IRTC
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
iRhythm Holdings, Inc. (IRTC) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | D+ (1.7) | C+ (2.5) | B- (3.1) | C (2.2) | F (0.0) | C- (1.9) |
| 2026-11-05 | D (1.2) | B (3.4) | B- (3.1) | C+ (2.7) | C+ (2.7) | C+ (2.6) |
| 2026-10-29 | D (1.2) | B (3.3) | B- (3.1) | C+ (2.6) | C+ (2.7) | C+ (2.6) |
| 2026-10-22 | D (1.3) | B (3.3) | B- (3.1) | C+ (2.5) | C+ (2.6) | C+ (2.6) |
| 2026-10-15 | D (1.4) | B (3.3) | B- (3.1) | C (2.3) | C+ (2.6) | C+ (2.6) |